{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-013872","form_type":"8-K","ticker":"TELO","cik":"0001971532","company_name":"Telomir Pharmaceuticals, Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.908520+00:00","generated_at":"2026-05-15T08:15:36.542139+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Telomir regains Nasdaq compliance on annual meeting requirement","bullets":["Received letter from Nasdaq on March 30, 2026 confirming compliance with Rule 5620(a).","Compliance achieved after holding the 2025 Annual Meeting of Shareholders.","Nasdaq has determined the matter closed.","No further actions required from the company regarding this deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-013872","json":"https://secwatch.observer/filing/0001493152-26-013872.json","markdown":"https://secwatch.observer/filing/0001493152-26-013872.md","text":"https://secwatch.observer/filing/0001493152-26-013872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226013872/0001493152-26-013872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1971532/000149315226013872/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:15:36.542139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}